On August 28, AIRDOC-B (2251.HK) announced its 2025 interim results. During the reporting period, AIRDOC-B continued to advance AI applications and deepen its diagnostic integration strategy, achieving a return to profitability with a net profit of 443,000 yuan, while treatment business revenue accounted for 31.6%. Through AI technology-driven initiatives, AIRDOC-B not only achieved cost reduction, efficiency improvement, and profitability on the operational front, but also continued to breakthrough in product innovation and R&D, accelerating global AI deployment and diversified market expansion, laying a foundation for long-term steady development.

**AIRDOC-B's Three AI Product Lines Drive Forward, Diagnostic Integration Strategy Accelerates Implementation**

The retinal detection AI product conducted 3.3 million UV tests in the first half of 2025, representing an 11.4% year-over-year increase. By the end of the reporting period, cumulative major positive cases discovered reached 100,000. These early-detected severe cases not only effectively reduced the long-term disease burden on individuals and families, but also decreased labor force losses and medical resource consumption caused by diseases at the societal level, injecting strong new AI momentum into the implementation of the "Healthy China" strategy.

This achievement, which combines business breakthroughs with social value, benefited from the continued growth and deepened coverage of retinal detection AI product service networks. In the first half of 2025, active service locations for this product reached 7,180, up 20.7% year-over-year. Among these, active locations in tier hospitals numbered 346, up 41.8% year-over-year, with detection UV reaching 196,000, up 35.0% year-over-year.

Myopia prevention AI and visual training AI innovative intervention products also accelerated deployment, with the diagnostic integration strategy showing effectiveness. During the reporting period, myopia prevention AI usage UV reached 2.812 million, up 68.1% year-over-year, serving 58,000 users; visual training AI training UV reached 1.026 million, up 11.6% year-over-year, with home training serving a cumulative 36,000 users and in-clinic training serving a cumulative 237,000 users. The innovative deployment of AIRDOC-B's myopia prevention and visual training AI products is expected to alleviate the "supply-demand contradiction" in adolescent myopia prevention and control resources, promote the transformation of eye health from "passive treatment" to "active intervention," reduce the "time and economic costs" of family eye health management, and protect families' bright future vision.

**Technology Advantages Lead the Way, Myopia Prevention AI Ushers in Large Language Model Era**

During the reporting period, AIRDOC-B continuously launched innovative products and technology upgrades. In the myopia prevention AI field, AIRDOC-B's myopia prevention AI product successfully integrated with the Wanyu large language model, transforming it from a single treatment tool into a "family optometrist" with autonomous decision-making capabilities. By precisely tracking axial length changes, generating structured visual health reports, and providing data-based personalized intervention recommendations, it not only optimized the effectiveness of photobiomodulation therapy (PBMT) but also constructed a scientific and systematic myopia prevention and control management system for users.

In January 2025, the new generation portable fundus camera (AI-FD16U) was officially approved. This compact and lightweight fully automatic AI fundus camera weighs only 1.3kg, covering less than an A4 paper area, and adopts touchscreen + voice interaction + Wanyu large language model, making vascular and neural health monitoring accessible anytime, anywhere.

In February, the AIRDOC-B Wanyu large language model completed a comprehensive upgrade. Leveraging generative artificial intelligence technology, it has been applied in multiple fields including AI fundus detection, AI myopia prevention, AI visual training, and AI primary examination.

In May, AIRDOC-B's artificial intelligence stress resistance detection device officially launched. Through dynamic autonomic nervous system holographic technology and eye tracking technology under visual stimulation, it provides non-contact measurement, accurately assessing five key indicators including stress resistance, psychological pressure, physical pressure, autonomic nervous balance, and activity in 90 seconds.

Additionally, on April 10, AIRDOC-B's AIFUNDUS 2.0 multi-disease AI diagnostic system for fundus examination received NMPA Class III medical device certification, significantly improving grassroots screening and clinical auxiliary diagnostic efficiency. Simultaneously, digital occlusion therapy obtained a national invention patent, solving the problem of poor patient compliance and providing scientific basis for doctors to adjust treatment plans. By the end of the reporting period, AIRDOC-B obtained 13 new patents, bringing the cumulative total to 283 patents.

**AI Health Global Deployment Accelerates, Research Achievements Reach New Heights**

AIRDOC-B actively advances global deployment, driving diagnostic integration innovation through international cooperation. By the end of June, AIRDOC-B's AI product service networks have covered EU regions and countries including Singapore, Thailand, Indonesia, Vietnam, South Africa, Saudi Arabia, United Arab Emirates, Malaysia, Chile, and Mexico, promoting the universalization and democratization of global quality medical resources, leveling regional medical resource disparities, and supporting global green and low-carbon development. During the reporting period, overseas market revenue proportion increased to 12.3%.

During the reporting period, AIRDOC-B's research achievements continued to gain recognition from international authoritative journals. In May, a deep learning model jointly developed by AIRDOC-B and Beijing Anzhen Hospital research team, capable of accurately identifying mild cognitive impairment in coronary artery disease patients, was published in the international cardiovascular authority journal "Heart," providing scientific basis for early intervention of global coronary disease complications.

In June, AIRDOC-B's PanDerm AI skin cancer early screening system results were published in the top international medical journal "Nature Medicine," improving skin cancer early screening accuracy by 11% and providing efficient AI solutions for global skin cancer early screening. These research achievements not only further enhanced AIRDOC-B's international influence but also contributed to global medical and health development through technological innovation.